Human Epidermal Growth Factor Receptor Family-Targeted Therapies in the Treatment of HER2-Overexpressing Breast Cancer

Abstract

Purpose. Chemotherapy has been tested extensively in conjunction with standard therapy in the treatment of head and neck cancer, primarily in the form of neoadjuvant chemotherapy, but few trials have shown a survival benefit. Although a few studies have suggested that adjuvant chemotherapy given after standard treatment may improve survival, to date these trials have been troubled by various problems in design and dosing. The purpose of our trial was to determine the feasibility of giving moderately intensive chemotherapy exclusively after standard therapy, and to determine whether survival appeared to be improved as measured against historical data. Methods. We used adjuvant chemotherapy in two groups of patients with squamous cell carcinoma of the head and neck: group A consisted of 46 patients with newly diagnosed stage III and IV disease, and group B consisted of 46 patients with relapsed disease having been treated with salvage surgery. In all patients, the intended adjuvant chemotherapy consisted of two cycles of combination cisplatin, bleomycin, and infusional 5‐fluorouracil (5‐FU) given three weeks apart, followed by four cycles of bolus methotrexate, 5‐FU, and bleomycin given every two weeks. Results. In group A, the two‐year survival was 72%. In group B, the two‐year survival was 58%. Conclusion. Compared to the vast majority of similarly staged patients with head and neck cancer reported in the literature, the survival of our group seemed considerably better, suggesting that a definitive randomized study testing this schedule of adjuvant chemotherapy is warranted.

Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells

“…HER2/Her3 heterodimers directly phosphorylate the p85 regulatory subunit of PI3K activating the PI3K/Akt pathway(29). In parallel, HER2/EGFR heterodimers also activate the MAPK pathway in most cases(30).…”

Research priorities in metastatic breast cancer: A James Lind Alliance Priority Setting Partnership

“…Estrogen receptor (ER) and progesterone receptor (PR) have the longest history of utility as biomarkers for treatment of MBC with endocrine therapies . Testing for human epidermal growth factor receptor‐2 (HER2) is now standard for predicting the response to anti‐HER2 therapy . In practice, we group into ER‐positive, HER2‐positive, or triple‐negative, but know from The Cancer Genome Atlas (TCGA) breast cancer data that these groups have vast heterogeneity .…”

“…6 Testing for human epidermal growth factor receptor-2 (HER2) is now standard for predicting the response to anti-HER2 therapy. 7 In practice, we group into ER-positive, HER2positive, or triple-negative, but know from The Cancer Genome Atlas (TCGA) breast cancer data that these groups have vast heterogeneity. 8 A significant proportion of patients will not express any of these receptors (ie triple-negative), or do express receptors but do not respond to available therapies.…”

Regional Delivery of Chimeric Antigen Receptor–Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain

“…Approximately 20% to 25% of breast cancers overexpress HER2 (2), which is an established therapeutic target of both mAbs and receptor tyrosine kinase inhibitors. With the advent of effective mAbs directed against HER2, the median overall survival of patients with metastatic HER2 þ breast cancer has improved (3).…”